Hepatitis C Virus: No Longer a Barrier to Oncology Care

Sobia N. Laique, Hugo E Vargas

Research output: Contribution to journalArticle

Abstract

Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

Original languageEnglish (US)
Pages (from-to)207-208
Number of pages2
JournalThe American Journal of Gastroenterology
Volume114
Issue number2
DOIs
StatePublished - Feb 1 2019

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Hepatitis C Virus: No Longer a Barrier to Oncology Care'. Together they form a unique fingerprint.

  • Cite this